Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Technology appraisal guidance
Reference number: TA1065
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.